ESMO in Focus: Targeting rare oncogenes and kinase inhibitor resistant tumours
Four leading Australian experts discuss presentations from the 2021 European Society of Medical Oncology (ESMO) meeting on the landscape of genetic testing and treatment for rare fusion oncogene mutation associated thyroid and lung cancers, focusing on RET fusion positive cancers
Sign up for free and continue reading
Med CPD offers the widest range of courses and content, all accessible in one place. Click on the Sign up button and start looking after the health of your career.
MDBriefCase Group Inc.
Speakers
Dr Malinda Itchins
Professor Duncan Topliss
Professor Kenneth Ou2019Byrne
Professor Sandra Ou2019Toole
Duration
1 H